Lund, Sweden - February 10, 2026 -Active Biotech (NASDAQ Stockholm: ACTI) today received positive feedback on its clinical proof-of-concept trial with tasquinimod in myelofibrosis. The study will now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results